



Inspired by lifestyle, driven by opportunity.



BIOMEDICAL INDUSTRY CAPABILITY GUIDE



Welcome to the Gold Coast

The Gold Coast is a city like no other – inspired by lifestyle and driven by opportunity.

Over the past decade, our local economy has broadened with significant growth in industry sectors including marine, film, education, the arts and medical research.

Today, the health care and social services sector is worth \$3.8 billion annually to our local economy, rivalling tourism which contributes around \$3 billion.

We are investing heavily in the Gold Coast Health and Knowledge Precinct, in partnership with state and federal agencies and the private sector.

This precinct is symbolic of our city's future – a destination where the world's best medical research and innovation can flourish.

The coast's biomedical sector is expanding thanks to the vision of our city's world-leading institutions, research facilities, hospitals and start-up enterprises.

Now is the time to join us on this exciting journey into a future where innovation is rewarded and where excellence thrives.

That place is the Gold Coast. Be part of the future.

A stylized, handwritten signature in black ink that reads "Tom Tate".

Mayor Tom Tate
City of Gold Coast



“Over just two decades we have created a unique translational research institute, that now has a rich research pipeline, a drug accessible under the special access scheme to treat viral-induced arthritis and another drug and two vaccine candidates continuing in human clinical trials. That’s a remarkable achievement.

When I look at it now, it has just surpassed any expectation or hope I ever had.

I never could have predicted 23 years ago that we would have the Health and Knowledge Precinct, two hospitals, the university and so many industry players all right here. That’s just been a beautiful thing to see.

The opportunities we have here are why there is no other major precinct in the country that can match the powerhouse we provide.”

Mark von Itzstein AO, Director, Institute for Glycomics

“There’s an appetite for innovation and entrepreneurship, not just in medicine, but in business and entertainment, and a range of other industries.

We’re part of an international community, in research and teaching, and in giving back and this benefits our patients first and foremost, and our international reputation means we’re working with most of the multinational companies, many of who are moving to the Gold Coast because they see the benefits of what we are doing and planning in the health and knowledge precinct, it ticks a lot of their boxes.”

Dr Hal Rice, Director of Interventional Neuroradiology, Gold Coast University Hospital

“On the Gold Coast, we’re not just building a healthcare future; we’re cultivating a thriving ecosystem of cutting-edge research and groundbreaking technologies. Success is achieved through small actions that lay the foundation for extraordinary achievements; recognising that every member of our ecosystem plays a vital role in shaping our collective success. At BiomeCentric, as leaders in microbiome science, we’re proud to contribute to this incredible journey.”

Shaun Roux, CEO of BiomeCentric



Professor Mark von Itzstein AO, Director, Institute for Glycomics



Gold Coast, Australia

The Gold Coast is a city coming of age. It is a place of opportunity that, over the next decade, is transforming into a globally-recognised city while retaining its enviable lifestyle and stunning natural environment.

Strategically located on the edge of the Asia-Pacific rim, with access to two international airports, the Gold Coast is perfectly positioned as a destination for business, investment, study, research, sport, events, tourism and lifestyle.

The Gold Coast stretches along 57 kilometres of coastline and is home to over 600,000 people. Beyond the city's beautiful beaches are vast, sub-tropical rainforest with breathtaking scenery.

The Gold Coast forms a vibrant part of the dynamic South East Queensland (SEQ) region, a conglomeration of 3.5 million people that will play host to the 2032 Olympic and Paralympic Games.

Welcoming close to 13 million visitors each year, the Gold Coast is Australia's premier tourist destination, offering a vibrant mix of shopping, entertainment, theme parks, restaurants, entertainment and an abundance of natural attractions.

With a robust economy valued at \$40.98 billion, and an ambitious strategy that encourages innovation and sustainable growth, the Gold Coast's future is full of promise.

Ours is an economy of opportunity that has grown from its basis in tourism and construction to a diverse, knowledge-based economic environment.

Gold Coast Biomedical Industry

The Gold Coast biomedical sector is growing quickly, directly employing 1800 highly skilled workers and directly contributing \$300 million to the local economy.

Investment in the sector continues to grow with over \$5 billion invested in the Gold Coast Health and Knowledge Precinct (GCHKP), Asia-Pacific's emerging health and knowledge hub. The Precinct is home to the Gold Coast University Hospital, research and allied medical facilities, including Griffith University, the Institute for Glycomics and the Menzie's Health Institute Queensland. The next stage of the GCHKP is supporting the relocation and expansion of global enterprises into the Precinct.

The Precinct anchors the city's health and medical industry and provides a unique innovation cluster to support leading health services, research innovation, world-class education and commercialisation of new products and services.

Operating under high Australian standards and locally held intellectual property, Gold Coast businesses are gaining international recognition and demand for quality products and services; from supplements and pharmaceuticals to medical devices and specialist treatments.

Clinical Trials

The Gold Coast has significant clinical trial capability and continues to grow rapidly. The capability is underpinned by globally recognised researchers, a leading university hospital, multiple universities, private hospitals, an ageing multicultural population and national benefits associated with tax incentives and regulatory processes that make Australia a highly cost competitive location for clinical trials.

From Phase I-IV, a broad range of clinical trial categories are catered for in both hospital and university facilities for a range of drugs, vaccines, device and therapeutic treatments.

Research Strengths

- Drug, vaccines and diagnostics.
- Glycomics-based drug discovery and translation.
- Infectious Diseases and immunology.
- Neuroimmunology including Long Covid.
- Personalised medicine – medical devices and surgeries.
- Advanced design and prototyping.
- Advanced neurorehabilitation and disability research.
- Spinal Cord Injury repair and rehabilitation.
- Neurovascular treatments and technologies.
- Neurodevelopmental conditions.
- AI and Digital Health.
- Nursing and Allied Health.



Gold Coast Health and Knowledge Precinct

The 200-hectare Gold Coast Health and Knowledge Precinct (GCHKP) is at the centre of the city's biomedical sector and the focus for research and development (R&D) in the industry.

With world-first facilities, leading translational research, and a rapid post-COVID expansion of clinical trial capability and new developments, the GCHKP is fast emerging as an Asia-Pacific hub for medical technologies.

Home to two major hospitals, including the Gold Coast University Hospital (GCUH), two significant biomedical research institutes and comprehensive health education at Griffith University, and boasting three clinical trial units, the GCHKP also includes exciting biomedical start-ups.

The Lumina commercial cluster offers 9.5 hectares of development-ready land for co-location of life sciences, health and technology businesses. This opportunity is taking shape with projects like the new Proxima and RDX Lumina underway.


Our 20,000 students at Griffith University's Gold Coast campus and the Queensland Academies Health Science campus, represent the skilled workforce of the future. Global health and biomedical brands doing business in the GCHKP include pharmaceutical giant Sanofi, healthcare technology leader Philips and US-based medtech company BIVACOR, which has developed a world-first rotary total artificial heart that is set for human clinical trials by 2025, and which bases a key team in the GCHKP to work alongside specialist mechanobiology researchers. From the founding of Griffith's Institute for Glycomics 23 years ago, to the establishment of the university's medical school in 2005, the opening of GCUH and the launch of Australia's leading healthtech accelerator LuminaX in 2021, growth of the GCHKP as a biomedical hub has been steady but impressive. www.gchkp.com.au

Leading growth in the GCHKP's cutting-edge infrastructure is the NeuTex image-guided surgery training and robotics centre, the world's only facility of its kind outside a hospital dedicated exclusively to training and R&D, which opened in May 2023 in partnership with Philips.

Co-founded by globally renowned interventional neuro-radiologists Dr Hal Rice and Dr Laetitia de Villiers, NeuTex attracts specialist doctors from across the Asia-Pacific to learn the latest stroke and brain aneurysm procedures and trial new medical devices developed by global companies. Together they have conducted the largest caseload of robotic aneurysm repairs globally.

'We're expanding R&D in the neurovascular field while also broadening training in other surgical specialties such as cardiovascular and spinal and eventually orthopaedics,' says Dr Rice. 'That includes utilising personalised 3D-printed models to revolutionise training and a future where AI and robotics will enable remote procedures, virtually anywhere in the world.'





Yatala-Stapylton

Probiotics Australia

Gold Coast Health and Knowledge Precinct

Gold Coast University Hospital
Gold Coast Private Hospital

Griffith University
Institute for Glycomics
Menzies Health Institute
Queensland

Advanced Design and
Prototyping Technologies
Institute

Griffith University Clinical Trial
Unit

GCUH Clinical Trials Unit
Gold Coast Private Hospital
Clinical Trials Unit

Bio-Az
Bivacor
DatarWe
Intelli HQ
Materialise
Maverick Bio
NeuTex & Phillips
Ontic Ortho
Sanofi

Coomera Central

Home of future health precinct

Coomera Connector

Stage 1 | \$2.1B investment

Tourism strip

Southport CBD

Tasman Oncology Research

Gold Coast Cultural Precinct

BiomeCentric
Prorenata Biotech

Pindara Private Hospital

Robina Central

Robina Private Hospital
Bond University
Research Institute for Future Health

Gold Coast Light Rail

Stage 3 | \$1.2B investment

Gold Coast Airport

John Flynn Private Hospital
Southern Cross University

The Gold Coast is a linear city bordered by the Pacific Ocean to the east and the hinterland to the west. The GCHKP represents the core of the biomedical sector on the Gold Coast with satellite research, innovation hubs and manufacturing capability throughout the City.

Infrastructure hub

Area of high economic activity

- 1 Northern Gateway
- 2 The Broadwater
- 3 Central Core
- 4 Southern Gateway
- 5 The Hinterland

Capability guide

Institutions		Biomedical Organisations	
Gold Coast University Hospital	14	BioAz	28
Gold Coast Private Hospital	14	BiomeCentric Pty Ltd	29
John Flynn Private Hospital	14	Bivacor®	30
Robina Hospital	14	DatarWe	31
Robina Private Hospital	14	IntelliHQ	32
Pindara Private Hospital	14	Materialise	33
Griffith University	15	Maverick Bio	34
Institute for Glycomics	16	NeuTex & Phillips	35
Menzies Health Institute	17	Ontic Ortho	36
Advanced Design and Prototyping Technologies Institute	18	Probiotics Australia	37
Bond University	20	Prorenata Biotech	38
Southern Cross University	21	Sanofi Anz and Translational Science Hub	39
Research & Clinical Trials		Sector Supporting Organisations	
Griffith University Clinical Trials Unit	23	COHORT	41
Gold Coast University Hospital Clinical Trials Unit	24	Gold Coast Health and Knowledge Precinct Office	42
Gold Coast Private Hospital Clinical Trials Unit	25	Lumina Gold Coast	43
Tasman Oncology Research	26	My Medical Department	44
		Tampe Consulting	45
		The Gild Group	46

INSTITUTIONS



Hospitals

The Gold Coast has two public hospitals and four private hospitals that service the Gold Coast region. A number are featured below.

Gold Coast University Hospital (GCUH)

Located in the GCHKP, GCUH is the largest public hospital on the Gold Coast and one of Queensland's largest clinical teaching and research facilities, with seven main buildings and a total floor space of 170,000 square metres.

Facilities include a trauma center, emergency department, maternity ward, intensive care unit, surgical suites, and various specialist clinics. Research specialties at GCUH encompass cancer research, clinical trials, medical innovation, and collaboration with Griffith University for medical education and research.

GCUH is one of Australia's largest teaching hospitals, with the busiest emergency department, providing comprehensive tertiary care and more than 900 beds.

It was named in Newsweek's 2023 World's Best Smart Hospitals – 224 in the world and sixth in Australia.

67 new research projects started in 2021-22 across Gold Coast Health (Covid-impacted), with 58 active clinical trials and 30 principal investigators across 17 departments supported.

Gold Coast Private Hospital

This private hospital in the GCHKP offers medical and surgical services, such as orthopaedics, cardiology, and maternity care.

John Flynn Private Hospital

Located in Tugun at the southern end of the Gold Coast, John Flynn Private Hospital is a prominent private healthcare facility. Services include maternity care, cardiac services and orthopaedics surgery.

Robina Hospital

Situated within the Robina Health Precinct, this 364 bed public hospital provides a wide range of healthcare services. Facilities include 24 hour emergency care, maternity, surgery, outpatient clinics, and specialized units.

Robina Private Hospital

Robina Private Hospital is a 90 bed private hospital with three specialist wards along with consultancy, outpatient, psychiatric day programs, day surgery, general medical and rehabilitation services.

Pindara Private Hospital

Pindara Private Hospital, in Benowa, offers a wide array of medical and surgical services. Facilities include maternity care, cardiac services and orthopaedics.

Note: The future Coomera Health Precinct is in development

Griffith University

Consistently ranked in the top 2% of universities globally and a Top 50 institution under 50 years old, Griffith is a research-intensive university catering to 50,000 students and spanning five campuses across Southeast Queensland, the largest being the Gold Coast campus (approximately 20,000 students).

Griffith is a values-driven university with a commitment to its vision of creating a better future for all. With 4,000 staff, 250,000 alumni from 130 countries and Australia's most awarded teachers, Griffith's research is highly ranked at world-standard or above across more than 50 disciplines including 2nd in the world in nursing.

Biomedical research strengths in the Gold Coast Health and Knowledge Precinct (GCHKP) centre on the Institute for Glycomics and the Menzies Health Institute Queensland, with Griffith Health Group actively translating research into clinical practice through conjoint appointments with Gold Coast University Hospital (GCUH).

Specialist 3D design and printing and MedTech engineering capabilities at the Advanced Design and Prototyping Technologies Institute (ADaPT) support development of cutting-edge personalised medical devices, surgeries and surgical training. A dedicated Clinical Trial Unit supports university researchers and external trials in the GCHKP (see page 23).

Products and services

- Undergraduate and post-graduate education.
- Degree programs and micro-credentials.
- Research education.

- Comprehensive research for translation, clinical trials and research commercialisation.
- Key biomedical research – Institute for Glycomics, Menzies Health Institute Queensland, Griffith Institute for Drug Discovery and research services such as the Clinical Trial Unit and BioBank.
- Industry and community engagement for impact.
- Leading technologies/projects – Glycomics-based drug and vaccine technologies, BioSpine, Spinal Injury Project, Chronic Fatigue Syndrome/Long Covid diagnosis and treatment, mRNA/RNA vaccines and therapeutics (including Translational Science Hub with Sanofi and other partners).

Accreditations and awards

- Ranked in Top 100 universities worldwide against the UN's 17 Sustainable Development Goals (SDGs), in the Times Higher Education Impact Rankings 2021-2023.
- Academic Ranking of World Universities: 201–300, QS World University Rankings: 243.
- More Australian Awards for University Teaching than any other university, since 2012.
- Global subject rankings - Nursing and Midwifery (second globally, first in Australia).

Contact P +61 7 3735 7111
griffith.edu.au



Griffith University's Institute for Glycomics

The Institute for Glycomics is a world leader in the discovery and development of next-generation drugs, vaccines and diagnostics that fight diseases of global impact.

It is the only institute of its kind in Australia and one of only a handful in the world focused on translating discoveries from the study of the carbohydrate or sugar language of the body and its role in disease processes.

As a GCHKP flagship Institute, it boasts more than 200 researchers and was established by renowned scientist Professor Mark von Itzstein AO (co-inventor of a world-first flu drug now marketed as Relenza) in 2000 and continues to attract >\$15 million in research income per annum.

The Institute engages globally with industry, philanthropic organisations, government and other premier research institutes to drive healthcare solutions that address some of the world's most intractable diseases including infectious diseases, cancers and neurodegenerative disorders.

Clinical trials and pre-clinical development are underway for a range of Institute technologies including a vaccine candidate for streptococcal A (in a Phase 1 trial in Canada), a sepsis drug candidate (Phase 1b), a gonorrhoea vaccine candidate and a viral-induced arthritis drug.

License agreements are in place with Biotechs in Australia, Switzerland and China.

Products and services

- Streptococcus A Vaccine (prevention of rheumatic heart disease).
- Parasite vaccine platform for babesiosis.
- Whole parasite malaria vaccine.
- Novel therapeutics to treat Group A strep and STSS.
- Novel treatment for gonorrhoea in females.
- New advances in cancer treatments.
- Label-free detection technology.
- Immunomodulatory evaluation platform.
- Facilities for potential collaborative use Glycobioanalytical Facility, Advanced Mass Spectrometry Facility, Separations Science Facility, Flow Cytometry Facility, Spectroscopy Facility, X-ray Crystallography, XymeBank.



Contact E glycomicsbusiness@griffith.edu.au
griffith.edu.au/institute-glycomics



Menzies Health Institute Queensland (MHIQ)

MHIQ, Griffith's largest research institute, umbrellas research across health fields, designed to be translated into clinical practice. The institute undertakes research across the lifecycle to identify key factors that influence health.

700 researchers collaborate across three overarching programs—Disability and Rehabilitation, Healthcare Practice and Survivorship, and Infectious Diseases and Immunology—encapsulating research strengths and aligning with local and national health priorities.

These programs are augmented with a Clinical Trial Unit, the Gold Coast BioBank, the Centre for Applied Health Economics and experts in biostatistics. Griffith's First People's Health Unit also intersects with MHIQ researchers to support Indigenous Health research.

Products and services

- Griffith Centre of Rehabilitation and Biomedical Engineering (GCore) – personalised digital twin modelling and technologies for rehabilitation, surgeries, medical devices and training programs – key projects/technologies include BioSpine and Digital Athlete.
- National Centre for Neuroimmunology and Emerging Diseases – world-leading research and translation for Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis and Long Haul Covid.
- Clem Jones Centre for Neurobiology and Stem Cell research – spinal cord injury repair technology, Alzheimer's research.
- Hopkins Centre – Disability and rehabilitation research and policy, Griffith Inclusive Futures.

- Healthcare Practice and Survivorship research – neuroscience, ageing and dementia, health care systems, healthy lifestyles, wound care, mental health, neurodevelopment, cancer survivorship.
- Infectious Diseases and Immunology – cell and gene medicine for infectious diseases and cancers, gene editing, genetic diseases, emerging viruses and therapeutics, infection and immunity, spatial biology.
- Gold Coast Biobank - 10,000 biospecimens available for research, storage and database management, client biobanking services.
- Centre for Applied Health Economics.
- Clinical Trial Unit.



Contact P +61 7 5678 8664
E mhiq@griffith.edu.au
griffith.edu.au/menzies-health-institute-queensland



Griffith University's Advanced Design and Prototyping Technologies Institute (ADaPT)

ADaPT brings together multi-disciplinary expertise across Griffith University in collaboration with leading industry partners to push the boundaries in advanced custom design, rapid prototyping and new materials, in what is called the 'next industrial revolution' or Industry 4.0.

ADaPT enables the development of personalised medical devices and implants, bespoke surgery design, and surgical training models, working closely with researchers from the Griffith Centre of Rehabilitation and Biomedical Engineering (GCore) and with leading industry and clinical partners.

With advanced design at its centre and collaboration at its core, ADaPT combines leading-edge expertise in micro and nanoscience, complex imaging, 3D digital scanning, 3D functional modelling, bioengineering, industrial design, big data analytics, artificial intelligence and specialist expertise in designing advanced manufacturing processes.

A core enabler of growth in the GCHKP, ADaPT is equipped with extensive 3D printing technologies including multiple metal, polymer and bio printing capabilities and also boasts a range of equipment for testing of materials and devices.

ADaPT has the capability to underpin growth in point-of-care personalised medicine working with clinicians at leading hospitals.

Products and services

- Metal additive manufacturing.
- Polymer additive manufacturing.
- Composite additive manufacturing.
- Post processing.
- Analysis and advanced characterization.
- Design software and services.
- Contract research.
- Consultancy.



Key technologies

Tackling Spinal Cord Injury

BioSpine

BioSpine is developing an advanced neurorehabilitation system to create an immersive and intensive exercise therapy that promotes neuro-recovery from spinal cord injury (SCI).

It uses artificial intelligence (AI) to link a digital twin of the SCI patient with a brain computer interface that captures their intention to cycle on a motorised ergometer bike, activating their muscles using functional electronic stimulation and providing sensory feedback through virtual reality. Exercise is combined with drug therapy.

Spinal Injury Project

The Spinal Injury Project has developed a novel regenerative medicine therapy involving the transplantation of patented nerve bridges created with the patient's olfactory nerve cells to promote neural repair at the injury site, and paired with intensive exercise therapy pre and post transplantation to stimulate neuro recovery.

The two teams work with ADaPT to customise technologies or develop training tools using their specialised 3D design, materials testing and printing capabilities and both are proceeding through clinical trials.

Pioneering Long Haul Covid research

Researchers at Griffith's National Centre for Neuroimmunology and Emerging Diseases are at the forefront of diagnosing and

developing treatments for Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ ME), a debilitating condition that has not been well-understood, and have now taken a global lead in understanding Long Haul Covid and its potential links to CFS/ME.

Researchers believe there is considerable overlap in the pathology of the diseases and are probing the role of ion channel function and calcium signaling in the pathomechanisms. They hope to better understand the nature of the diseases and work to translate treatments.

\$280m Translational Science Hub with Sanofi

A new generation of mRNA vaccines and technologies is set to be developed at Griffith University in partnership with global pharma giant Sanofi, the University of Queensland and the Queensland Government.

Griffith's facilities and expertise in the Gold Coast Health and Knowledge Precinct – the Institute for Glycomics, Menzies Health Institute Queensland and the Griffith Clinical Trial Unit, will be critical to the success of the world-first initiative.

The Translational Science Hub in Queensland will work closely with the Sanofi mRNA Centre of Excellence in France and the US.

With the benefits of (mRNA) technology proven in the development of Covid 19 vaccines the future is bright.

Contact P +617 5552 8623
griffith.edu.au/advanced-design-prototyping-technologies-institute



Bond University

From health and medical exploration to real-world big data applications, Bond's research portfolio reflects the University's spirit of innovation, entrepreneurship, and independence.

The community of researchers represents a cross-section of accomplished professionals in their chosen field; attracted to the University by the focused support and resources available to Bond research academics and students.

Bond has two main Life Sciences Research Centres:

The Clem Jones Centre for Regenerative Medicine are at the cutting edge of stem cell science, investigating the therapeutic use of stem cells in tissue repair, particularly for degenerative eye conditions such as Age-related Macular Degeneration.

The Centre for Urology Research is focussing on enhancing knowledge and understanding of the lower urinary tract, with the aim of developing new treatments or improving current treatments for diseases and disfunction of the bladder and prostate.

Products and services

- Production of retinal cells from stem cells.
- Regeneration of retinal tissues from stem cells.
- Novel drugs to treat retinal diseases.
- Advanced cell therapies for vision loss.
- Modulation of overactive/underactive bladder.
- Treatments for prostate and bladder cancers.
- Management of urinary stones.
- Management of faecal incontinence.

Accreditations and awards

- Multiyear philanthropic donations from Clem Jones Foundation.
- Multiyear philanthropic donations from Estate of Cora Cutmore.
- 2 Pfizer Program research grants.
- 1 Cancer Council Queensland research grant.



Contact P +61 7 5595 5499
E nzwar@bond.edu.au
bond.edu.au/research/research-centres-and-institute

Southern Cross University

Southern Cross University (SCU) is a regional University situated across 3 campuses, including Yugambah campus at Coolangatta, Gold Coast, with four academic faculties, SCU College and Gnibi College.

SCU aligns education and research across four areas of urgent global need to create a better tomorrow for the community, the region and the planet. Harvest to Health, one of the research clusters, conducts fundamental and applied research to enhance the sustainable production of functional foods and natural products to assess their potential to optimise human and animal health and reduce the risk of disease. This research addresses UN SDG - Good Health and Wellbeing and contributes to better health for natural resources, people and communities, adding value for producers and consumers.

SCU's Harvest to Health research impact cluster is unique as it brings together research across the biomedical spectrum – from analytical chemistry, molecular biology and pre-clinical models to quality assurance, health and sustainable high-value farming. This broad research approach to health is enabled by SCU's world-class facilities, including TGA-accredited analytical chemistry laboratory, PC2 laboratory, imaging facility, clinical trials unit and bio-regions collaborative farming facilities. Biomedical researchers and infrastructure at SCU are well posed to address 'big picture' questions – from molecule to health outcome to sustainable future.

Products and services

- Evidence synthesis.
- Natural (plant and marine) chemistry laboratory services.
- Biomedical laboratory capability.
- Imaging facility.
- Human and animal health clinical research.
- Consulting.

Accreditations and awards

- One of only two TGA-accredited analytical chemistry laboratories.
- World-standard or above in 23 key research area (ERA 2018).
- Top 200 Young University in 2022 and one of few Universities in Australia to move up in 2023 rankings (Times Higher Education World University ranking).



Contact E andrea.bugarcic@scu.edu.au
scu.edu.au/research



RESEARCH AND CLINICAL TRIALS



Griffith University Clinical Trial Unit

Established in 2015 as a Core Research Facility to Griffith University, the Clinical Trial Unit (CTU) has since become a globally recognised, community centred clinical trial site that is underpinned by high quality, clinical care and research, openness and transparency, professionalism and ethical conduct.

The CTU supports university staff and collaborators to conduct a wide range of trials, but also offer professional clinical trial site services to commercial clients such as global Pharma, Contract Research Organisations and the biotech and nutraceutical industry.

The mission is to empower academic research and advance industry partnerships while providing the community with emerging and innovative treatment options.

The CTU is situated on Griffith University's Gold Coast campus adjacent to the Gold Coast University Hospital, and a short walk from the Gold Coast Private Hospital and the Gold Coast Health and Knowledge Precinct. This co-location supports ongoing staff education and important research collaborations in clinical trials.

Over the past 8 years, they have successfully conducted >50 commercial trials; achieving first patient recruited globally for a trial and becoming the top recruiter globally for another.

Products and services

- The CTU provides state-of-the-art, Good Clinical Practice compliant facilities suitable for phase I-IV clinical trials in various disease states.
- Staffed by highly experienced investigators and study coordinators that can provide trial start up, study coordinator, project

management and randomisation services.

- Experienced in a range of therapeutic areas: musculoskeletal, infectious disease, nephrology and renal disease, endocrinology/metabolic disorders, neurological diseases, cardiovascular conditions, gastroenterology, ear, nose and throat disease, respiratory diseases, ophthalmology, dermatology and women's health.
- Additional expertise in complementary medicine, vaccine development, pharmacokinetic investigations, technology and device trials, GMO trials and rare diseases.

Accreditations and awards

- CTU Team has multidisciplinary clinical trial experience from working in Australia and abroad.
- Managers are licenced Good Clinical Practice Trainers.
- CTU Team was Winner of Griffith University PVC Staff Excellence Performance Award in 2022.

Contact P +61 7 5678 0929
E clinicaltrialunit@griffith.edu.au
griffith.edu.au/clinical-trial-unit



Gold Coast University Hospital Clinical Trials Unit

Gold Coast Health can facilitate Clinical Trials of medicinal products, medical devices and biologics of all phases, from first-in-human to Phase IV.

The GCUH Clinical Trials Unit welcomes commercial opportunities across the health, medicine, biotechnology and pharmaceutical sectors. Their large recruitment pool and referral network includes people living in regional, rural, and remote communities.

In collaboration with partner organisations, they are driving future-focused change through a collective approach to address national, state and local initiatives and improve the translation of current evidence into healthcare practices and policies.

Many departments throughout Gold Coast Health are Clinical Trial active and have a dedicated Clinical Trial Unit to support health professionals offer Clinical Trial opportunities to our patients. The Gold Coast Health Clinical Trials Advisory Committee (CTAC) has oversight of the overall governance for clinical trial activity and service provision across Gold Coast Health, including Teletrials partner activity.

Gold Coast Health will be assessed against the National Clinical Trials Governance Framework. The Governance Framework embeds clinical trials into routine health service provision and strengthens the clinical and corporate governance arrangements for governments, hospital administrators, health services, private companies, trial sponsors and trial investigators and defines a clinical trial as “any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.”

Products and services

- A dedicated Clinical Trials Unit with space for infusion and day admissions.
- Experienced, GCP trained Principal Investigators across many disciplines.
- Trained and experienced clinical and enrolled nurse study coordinators.
- Trial start-up, research ethics and governance services.
- Integrated digital health care and PowerTrials (electronic research and clinical trials management system) for source data with remote access capability.
- 24-hour Pathology services (NATA accredited).
- Refrigerated and non-refrigerated centrifuges.
- Commercial grade data-logged fridges and -20 degrees and -80 degrees freezers.
- Dedicated Clinical Trials Pharmacy.
- Comprehensive trial categories including: Oncology, Haematology, Paediatrics, Emergency Medicine, Trauma, Critical Care, Maternal Foetal Medicine, Anaesthetics, Surgery, Cardiology, Endocrinology, Gynaecology, Neurology, Hepatology, Interventional Neuroradiology, Interventional Radiology, Renal, Respiratory, Orthopaedics, Vascular, Nuclear Medicine, Mental Health, Sexual Health, Digestive Health, Obesity, Palliative Care.

Gold Coast Private Hospital – Clinical Trials Unit

The Gold Coast Private Hospital – Clinical Trials Unit was established in 2022 and is a fully equipped site that offers Clinical trials from Phase I to IV that are catered for in both hospital and university facilities for a range of drugs, devices, and therapeutic treatments.

Facilities and operational capability enable pharmacokinetics sampling and -200C and -800C sample storage. The unit is supported by a Clinical Trials Pharmacy, Clinical Trials Nurses, Coordinators and a Manager.

The Clinical Trials Unit is part of the Gold Coast Private Hospital and as such has access to a number of services such as pathology laboratory, radiology, ICU and emergency department.

Products and services

- Phase Ib – IV clinical trials.
- Overnight stay trials and Day Infusion Clinic trials.
- Complex trials (interventional oncology, non-GMO cell therapy, medical device, surgery technique, robotics and trials requiring biopsy of tissues or other invasive techniques).

- Focus Areas: Oncology, Hematology, Chronic Respiratory Diseases, Endometriosis, Women's Health, Gastroenterology, Nephrology, Endocrinology, Neurology and Surgery (Medical Device).
- Collaboration with Griffith University (GU utilises the GCPH Pharmacy and Day Infusion Clinic and potentially GCPH Wards for short overnight stays).

Accreditations and awards

- National Clinical Trials Governance Framework Accreditation – Achieved Sep 2023.

Contact P +61 7 5687 0237
E ResearchGoldCoast@health.qld.gov.au
goldcoast.health.qld.gov.au/research/clinical-trials



Contact P +61 429 116 951
E michelle.cestari@healthscope.com.au
goldcoastprivatehospital.com.au



Tasman Oncology Research

Tasman Oncology Research is a leading provider of Oncology Clinical Trials on the Gold Coast. They partner with Australian and International Pharmaceutical, Biotechnology and Clinical Research Organisations to make novel treatments available to their patients.

Tasman have extensive onsite capabilities and access to external local vendors to provide trial support. They have experience in Phase I, II, III and IV trials, conducting trials in accordance with Good Clinical Practice quality guidelines, regulations and ethical principles.

Tasman employs a highly experienced team of Investigators and Clinical Research Coordinators who work diligently to foster collaboration and patient education. The Clinical Research Team brings experience from the pharmaceutical, academic and allied health industries.

They are committed to connecting eligible patients to ethically approved research and to maintaining patient safety and data integrity to the highest standards. We are proud to be able to provide our patients with access to trial opportunities.

Products and services

- Rheumatology Clinical Trials.
- Oncology Clinical Trials.
- Radiation Oncology Clinical Trials.
- On-site Clinical Trial Pharmacy Services.
- Genetic Counselling, Dietetics and Exercise Physiology service offerings through Tasman Health Care.

BIOMEDICAL ORGANISATIONS



Contact P +61 7 5613 2480
tasmanhealthcare.com.au/contact

 **Tasman Health Care**
Day Infusion Unit • Research • Pharmacy

Bio-az

Bio-az researches, develops, and produces functional ingredients. Bio-az ingredients can be easily formulated into a wide variety of human and animal products to deliver health and wellbeing benefits.

Globalisation changed how people consume food and the natural exposure to microbes in our diet. When communities grew and consumed their food their diet was from “paddock to plate”, exposing them to nature’s ecosystem of beneficial microbes essential for a healthy microbiome. By condensing populations in urban communities far from food sources, preservation of food became necessary, destroying the foods’ synbiotic microsystems. Pollution, dietary changes and less exposure to microbes have changed how our systems respond resulting in systemic illnesses in western societies such as diabetes.

Bio-az’s mission is to harness the intelligence of nature with the power of science to develop robust synbiotic (pre+pro+post biotic) ingredients to enrich lives, by delivering commercial B2B FMCG ingredient solutions for food, beverage and personal care manufacturers, paving the way for a healthier world where vibrant health ecosystems are an everyday reality. Bio-az develop synbiotic ingredients for people and animals with probiotics that survive the rigours of manufacturing, and maintain their stability at room temperature in high water and

carbohydrate products, for the shelf life of those products. Bio-az probiotic/synbiotic ingredients survive the acidity of the digestive tract, and germinate in the colon to deliver health benefits and beneficially modulate the microbiome.

Products and services

- Bio-az Food and Beverage Synbiotic Blends.
- Bio-az Oral Synbiotic blend (toothpastes/ mouthwashes/Oral health Gums/gummies).
- Bio-az Cosmeceutical Synbiotic Blend (wound care, skin conditions ,acne).
- Biotica Water (world’s first synbiotic water).
- Microbiome Analysis Whole.
- Whole Genomic and Metabolomic analysis.
- Synbiotic NPD for food and beverage manufacturers.
- Employment of six scientists.

Accreditations and awards

- Nutra Ingredients Asia Startup of The Year Winner 2021



Contact
P +61 484 819 370
E m.thexton@bio-az.com
bio-az.com



BiomeCentric Pty Ltd

BiomeCentric is Australia’s first Contract Development and Manufacturing Organisation (CDMO) dedicated to the Microbiome. The microbiome is a vital conduit to inside-out health and beauty.

Their mission is to change the paradigm when considering the development of active ingredients, finished goods, and personalisation of the products we use, focussing on eubiosis, subsequently nurturing long-term, resilient health and beauty.

BiomeCentric is driven to create, personalise, and develop products and ingredients that support the diverse microbial ecosystems in and on our bodies. Leveraging cutting-edge technology and decades of bioscience knowledge, they are committed to enhancing the well-being of both the host and their microbiota.

Their aim extends globally; sharing profound microbiome insights and empowering health and beauty brands worldwide. Their specialisation in microbiome-based products is paired with advanced manufacturing techniques applied throughout every phase, from meticulous lab testing to large-scale production.

BiomeCentric’s team can help in propelling a transformative journey toward microbiome-centric health and skincare. BiomeCentric leads the way with state-of-the-art microbiome skincare products and ingredients, setting new benchmarks in the beauty and wellness sector.

Products and services

- Turnkey Contract Manufacturing.
- Advanced Technologies and Product Delivery.
- Next-Generation Active Ingredients.
- Inner-Health products.
- Outer-Health products.
- Animal Care products.
- In Vitro and In Vivo Testing, Dermatological, and Clinical Trials.
- Personalisation – Microbiome Metagenome Profiling & Custom Formulation Design.

Accreditations and awards

- GMP ISO 22716.
- HACCP.
- ACO/USDA Organic.



Contact
P +61 7 5621 0097
E info@biomecentric.com.au
biomecentric.com.au



BiVACOR® is a clinical-stage medical device company developing the BiVACOR® Total Artificial Heart (TAH), designed to address the global unmet need of end-stage Heart Failure patients by providing a next-generation life-extending solution.

The BiVACOR Total Artificial Heart (TAH) combines magnetic levitation and rotary blood pump technology to create a small, durable and physiologically compatible device capable of replacing the complete function of the native heart.

BiVACOR is headquartered in Huntington Beach, CA, with additional offices in Houston, TX, and on the Gold Coast, Australia. BiVACOR was founded in 2008 by a team of internationally renowned biomedical engineers and cardiac surgeons, including Chief Technical Officer Daniel Timms, Ph.D. and Chief Medical Officer, William Cohn MD.

Today, BiVACOR has a robust collaborative network extending nationally and internationally, boasting a team of world-class engineers, medical specialists, and business executives fervent to advance this ground-breaking technology and focus on “Replacing Hearts and Restoring Lives.”

Products and services

- 1 product under development - BiVACOR Total Artificial Heart System.

Accreditations and awards

- Queensland nominee Australian of the Year 2023 (Daniel Timms).
- BiVACOR - Honorable Mention in Health Category of Fast Company's 2023 World Changing Ideas Awards.



Contact E admin@bivacor.com
bivacor.com



Datarwe is a clinical Data-as-a-Service provider operating as a public-private collaboration between healthcare providers and leading healthcare ecosystem partners.

They are united by the challenge of revolutionising medicine through enhanced real-world clinical data access. Their team of data scientists, engineers, and clinicians are passionate about increasing the adoption of medical AI innovation to the patient bedside and beyond.

The Clinical Data Nexus is a trusted research environment connecting approved users with over 13 million real world de-identified clinical data episode hours. Developed out of the need for advanced tools requiring large, cleansed data sets and rapid connectivity between hospitals, their research partners and the med-tech community.

Datarwe's mission is to accelerate the adoption of medical AI innovation to the clinician bedside and beyond by transforming the way hospital data is stored, handled and accessed. Datarwe connects hospitals, researchers, clinicians and developers with research-ready, enriched data through our Clinical Data Nexus.

Products and services

- Clinical Data Nexus is a dynamic, yet secure platform, built to translate and scale clinical research on real-world data into powerful tools that advance healthcare.
- 1 PLATFORM Datarwe's CDN is a singular point of connection to a vast network of local and international real-world data.
- 19+ HOSPITALS Datarwe's CDN links 19+ national and international hospitals.
- 13M+ EPISODE HRS Datarwe's CDN avails network participants to more than 13 million episode hours of curated data.
- Cleanse and label clinical data.
- Conduct research on clinical data.
- Explore data services for healthcare providers.
- Translate innovation into the healthcare system.

Contact P +61 7 3062 8455
E info@datarwe.com
datarwe.com



Formed in 2019, IntelliHQ (Intelligent Health Queensland) is a member-based, not-for-profit organisation closing the gap between medical and health professionals and technologists.

By promoting research, development and investment in artificial intelligence (AI), machine learning (ML) and big data technologies within the healthcare sector, IntelliHQ facilitates great improvements in healthcare workflows and delivery. IntelliHQ believe these beneficial tools will not replace, but support the already instrumental work of health professionals.

This vision supports a focus on awareness, advocacy, collaboration and innovation incubation. IntelliHQ strives to champion the responsible integration of AI, ML and big data innovations into healthcare systems and build translational confidence and knowledge in their use.

Their priority is to improve health outcomes across the board to support healthcare providers deliver exceptional, equitable care. Alongside their strong network of partners, IntelliHQ is pushing the medical space forward.

Products and services

- AI in healthcare training and education services.
- Improving patient outcomes and increase access to quality care by responsibly improving and integrating AI in healthcare systems.
- Providing a more equitable, accessible, affordable and efficient healthcare system empowered by AI.
- Uplifting the capabilities of clinicians by bridging the gap between medical professionals and innovative technology.

Accreditations and awards

- Awarded the MTPConnect REDi3.0 Grant to Meet Skills Gaps in the Medical Technology, Biotechnology & Pharmaceutical Sector.

Contact P +61 400 832 082
E info@intelliHQ.com.au
intelliHQ.com.au



Materialise incorporates nearly three decades of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of the 3D printing industry.

Materialise's open, flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D printing facilities in the world.

Materialise Medical, which has pioneered many of the leading medical applications of 3D printing, enables researchers, engineers and clinicians to revolutionize innovative patient-specific treatment that helps improve and save lives. Materialise Medical's open and flexible platform of software and services, Materialise Mimics, forms the foundation of certified Medical 3D printing, in clinical as well as research environments, offering virtual planning software tools, 3D-printed anatomical models, and patient-specific surgical guides and implants.

Products and services

- Materialise Mimics Innovation Suite, Industry-standard software for segmentation and anatomical analysis, planning, and design.
- Materialise Mimics inPrint quickly convert medical image data (DICOM files) to 3D

anatomical models by seamlessly integrating Mimics inPrint into the hospital's workflow.

- Materialise PROPLAN CMF™ empowers surgeons to make critical decisions preoperatively and helps to ensure better surgical outcomes. The software's dedicated workflows cover orthognathic procedures as well as mandible and midface reconstructions and distractions.
- Materialise OrthoView is a complete orthopedic planning solution, which comes with expert support as well as smart templating tools for joint replacement, trauma, osteotomy, spine, and pediatric procedures.
- Materialise Personalized implants:
 - Materialise Glenius, Personalized glenoid implants
 - Materialise aMace, Personalized acetabular implants
 - 3D Planning & Guides for Osteotomies

Accreditations and awards

- Materialise medical software had received FDA 510k clearance and are CE-marked.
- As providers of high-quality prototypes, production tools, medical devices and cutting-edge software, Materialise Manufacturing (Materialise NV) is ISO 9001 and ISO 13485, EASA Part 21G and EN 9100 certified. EASA Part 21G and EN 9100 certification allows authorized delivery of airworthy additive manufactured end-use parts.

Contact P +61 7 5678 0668
E medical@materialise.com.au
materialise.com



Maverick Bio

Maverick Biosciences produces and exports fresh animal materials, sometimes known as Animal Derived Biomaterials (ADB's) from Australia and New Zealand for the biomaterials market.

Exporting globally, they are creating and managing customised supply chains for Quality Manufacturing (GMP) environments such as Pharmaceuticals, Vaccines, Medical Devices (Dental and Cardiovascular), Medical Diagnostics, Nutraceuticals and other collagen based products.

Mavericks biosciences materials are utilised in the Medical Device, Regenerative Medicine, Dental, Diagnostic and Pharmaceutical markets.

With a strong belief that the quality of the ADB is closely related to the manner in which the materials it's treated at and post harvest, Maverick works closely with the abattoir industry, operating its own production teams to inside our suppliers, to ensure the materials of the highest quality are harvested in complete compliance with our clients' regulatory and quality requirements.

Maverick Biomaterials is an extension company that produces chemically crosslinked bovine and porcine pericardium for manufacturing of artificial heart valves to its customers globally.

Together the two companies are referred to as Maverick Bio.

Products and services

- Collagen Raw Materials.
- Bone Growth Substitute Raw Materials.
- Fixed Chemically Crosslinked Patches and leaflets.
- Regenerative Medicine Raw Materials.
- Bioactive ingredients for pharma.

NeuTex and Philips

The NeuTex Image-guided Therapy Training and Robotics Centre was established in 2023 in the Gold Coast Health and Knowledge Precinct in a partnership with multiple companies, including global healthcare leader Philips.

NeuTex is co-founded by Dr Hal Rice and Dr Laetitia de Villiers, globally renowned specialists who lead the Interventional Neuroradiology service at Gold Coast University Hospital. NeuTex is the first facility of its kind in the world outside a hospital, pioneering the use of technologies including 3D printed patient-specific anatomical models, artificial intelligence and robotics in the treatment of stroke, brain aneurysms and other neurological conditions. It will expand to provide training and support innovative R&D in cardiovascular, peripheral vascular, spinal, surgical and orthopaedic specialties.

NeuTex has equipped the centre with the latest Philips Azurion biplane system, a leading platform for interventional image-guided procedures.

Philips (Royal Philips: (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-

being and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.

Products and services

- Minimally-invasive endovascular surgical training.
- Neurovascular devices training and R&D.
- Pre-operative surgical planning.
- Specialist medical remote proctoring and mentoring.
- Medical device promotion and launch facility.
- Support facility for device and software clinical trials.



Contact P +61 2 6885 1200
E sales@maverickbio.com
maverickbio.com

MAVERICK BIO

Contact P +61 402 772 299
E har@neutexcg.com
philips.com/a-w/about/awards-and-recognition.html



Ontic Ortho Solutions Pty Ltd

Ontic Ortho Solutions Pty Ltd, aka “Ontic”, is an EduTech start up located in the heart of the Gold Coast. They are a pioneer in the biomedical realm, focusing on the intersection of orthopaedics and advanced training methodologies.

Their niche lies in crafting state-of-the-art orthopaedic surgical training models, aimed not only at enhancing surgical training but also showcasing the efficacy of orthopaedic devices.

Their dedication stems from a profound commitment to elevate patient outcomes by revolutionizing the domain of orthopaedic surgical training. Harnessing the power of biomedical research, cutting-edge technology, and custom-designed products, they create models that seamlessly integrate with medical devices, making surgical training more realistic and effective.

Ontic Ortho Solutions Pty Ltd expertise is further enriched by a team with accumulated decades of industry knowledge, not just in EduTech, but deeply rooted in the biomedical landscape. They are not just skilled; they are passionate about making a real difference in orthopaedic education. Proudly Australian-owned, with manufacturing anchored in Queensland, Ontic is synonymous with precision, personalization, and unparalleled service.

At Ontic, they believe in the transformative power of technology. Committed to innovation in the biomedical arena, their vision surpasses mere solutions; they aim to redefine the standards of orthopaedic surgical education.

Products and services

- Surgical Training Models.
- Display Models for Devices.
- Robotic Surgical Training Models.
- Veterinary Surgical Training Models.
- Digital Analysis of Surgical Planning and Performance.
- Customized Adaptation of Surgical Models.
- Unique Training Model Development.
- Designing Models for Product Launches.



Contact P +61 427 110 730
E info@onticortho.com
onticortho.com



Probiotics Australia

Probiotics Australia is the first TGA accredited cGMP manufacturing facility dedicated to make Probiotics. Their product is classified as a raw material ingredient for food and pharmaceutical industry.

They manufacture a range of Lactobacillus and Bifidobacterium strains in live and deactivated formats which they stock and have regular supply of. They also are open to contract manufacture research strains and take up commercialization projects from various stakeholders.

Their inhouse whole genome sequencing capabilities and quality systems ensure the probiotic ingredients sourced from our facility is manufactured under GMP guidelines using precision fermentation technology.

Products and services

- Inhouse manufacture of non-GMO Probiotics, postbiotics, ready-to-use blends and Pre-mixes using clinically researched as well as generic strains.
- Contract manufacturing of research and commercial strains.
- Scale up and commercialization projects for Probiotics and postbiotics.

- Whole Genome Sequencing and strain comparison.
- Turn-key solutions for food and pharmaceutical grade probiotic products.
- Distribution of globally sourced probiotic and postbiotic strains.

Accreditations and awards

- cGMP/TGA.
- US-FDA, Gold Coast Food License, Export accreditation (China).
- Halal, Kosher, Australian Certified Organic.

Contact P +61 5670 6466
E info@probioticsaustralia.com.au
probioticsaustralia.com.au



Prorenata Biotech

Prorenata Biotech is an emerging leader in Nanomedicine technologies focused on accelerating the development of transformative genetic medicines.

Headquartered on the Gold Coast, its mission is to overcome the bottlenecks limiting RNA/ DNA research and commercialisation through an integrated approach combining specialised expertise, collaborative partnerships, and cutting-edge infrastructure.

By expanding Lipid Nanoparticle (LNP) formulation, manufacturing, and analytical capabilities, Prorenata provides researchers and companies with the enabling technologies to progress from concept to clinic. Prorenata's formulation and quality systems promise to accelerate the screening and production of tailored formulations for diverse therapeutic needs.

Underpinning Prorenata's capabilities is a team of scientists passionate about catalysing medical innovation. Prorenata leverages its deep experience in formulation, gene medicine, characterization, and drug delivery to optimise and control the interface between payload and patient.

Prorenata aspires to consolidate Australia's strengths across the RNA value chain and attract investment in local capabilities. By connecting synergistic solutions from research to real-world impact, Prorenata aims to position Australia at the forefront of next-generation vaccines, drugs, and diagnostics. Prorenata's integrated infrastructure empowers local researchers and companies to unlock the full potential of genetic medicine.

Products and services

- **Lipid Nanoparticle Formulation Optimization:** Engineering and screening of novel LNPs tailored to therapeutic payload requirements using cutting-edge technologies.
- **Gene Medicine Design and Optimization:** Designing gene constructs and sequences optimised for stability and performance.
- **Preclinical Testing and Evaluation:** Rigorous in vitro and in vivo testing of gene therapeutics encapsulated in LNPs to evaluate the efficacy, safety, delivery, and pharmacokinetics per GLP standards.
- **Scalable Manufacturing:** Production processes designed for seamless scale-up from preclinical to clinical Good Manufacturing Practice (GMP)-grade manufacturing.
- **Regulatory Strategy:** Consulting on navigating the regulatory landscape and licensing opportunities to enable rapid progression from research to clinic.
- **LNP Analytical Characterization:** Comprehensive physicochemical and biological analysis and quality control of nanoparticle formulations using cutting-edge techniques.
- **Innovation Partnerships:** Collaborative R&D with industry, researchers, and clinicians to create an integrated ecosystem advancing RNA technologies from concept to commercialisation.

Sanofi Anz and Translational Science Hub

Sanofi is an innovative global healthcare company, driven by one purpose to, chase the miracles of science to improve people's lives. Their team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible.

Sanofi provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of its ambitions.

With a heritage spanning more than 125 years, their broad therapeutic portfolio includes therapies and vaccines across diabetes, cardiovascular disease, infectious diseases, oncology, immunology and rare diseases.

In Australia they are a leading supplier of medicines and vaccines. 95% of young Australian's will have had a Sanofi vaccine by age five, and one in four Australians has had one of their flu vaccines. More than 10.5 million prescriptions are filled in Australia for Sanofi products each year.

Their breakthrough research and unique collaborations allow us to accelerate access to scientific innovation and benefit the lives of the patients who depend on us. Clinical trials are an important phase of their research, and annually support access for hundreds of Australians to cutting edge scientific innovations.

While their local corporate headquarters are in Sydney, they have recently opened global R&D offices in Brisbane at the Translational Research Institute and on the Griffith University Gold Coast campus.

Products and services

- Vaccines for paediatric, travel, respiratory and other infectious diseases.
- Immunology.
- Rare Disease and Rare Blood Disorders.
- Oncology.
- Diabetes.
- Consumer Healthcare Products.
- Research and Development.
- Clinical Trials.
- Real world evidence research.
- Product commercialization.

Accreditations and Awards

- Named one of the most sustainability-committed companies by Standard & Poor's Global Ratings.
- 2023 Australian Financial Review Best Place to Work – Health.
- WEConnect 2022 Gold Global Champion for Supplier Diversity & Inclusion.
- Member of the Business Council of Australia, Medicines Australia and AusBiotech.



Contact P +61 7 3521 8523
E info@prorenata-biotech.au
prorenata-biotech.com



Contact P (TSH) +61 (0)7 3025 5010
P (ANZ) +61 (0)2 8666 2000
sanofi.com.au/en/contact-us



SECTOR SUPPORTING ORGANISATIONS



Cohort Innovation Space

Located in the heart of the Gold Coast Health & Knowledge Precinct at Cohort Innovation Space, the Cohort Labs empower bio-innovators and scientific entrepreneurs by providing them with access to state-of-the-art labs and office space to help them accelerate new ideas and research.

These modern, multi-disciplinary facilities provide scientists a home where they can develop and test new research, make valuable connections, scale quickly and commercialise their innovations.

Cohort operates in three buildings with over 2500m² space which includes 46 coworking desks, 32 private offices, three PC1 and PC2 research labs, five meeting rooms, two boardrooms, a 120 person event space, podcast studio, commercial coffee machine, bike racks, showers and end of trip facilities.

When you lease a Cohort Lab, your membership includes access to all Cohort shared facilities, the tenants share of all building outgoings, and utilities consumption including wifi internet.

Products and services

- PC2 laboratories.
- PC1 laboratories.
- General Office space.
- Business Support programs.

Accreditations and awards

- 2021 Rider Levett Bucknall Queensland State Development of the Year.



Contact P +61 5610 1906
E hello@cohortspace.com.au
cohortspace.com.au/science-labs-for-lease



Gold Coast Health and Knowledge Precinct Office

The Gold Coast Health and Knowledge Precinct (GCKHP) Office provides a professional coordination and concierge service for the Precinct, fostering collaboration to build the innovation ecosystem, promoting capabilities and overseeing attraction and curation of new entrants into the GCHKP, working alongside Economic Development Queensland (EDQ), experts in land-use development, placemaking and marketing.

The GCHKP Office works on behalf of partners Griffith University, City of Gold Coast and the Gold Coast Hospital and Health Service, and together with EDQ, to deliver on the Precinct's Strategic Plan 2022-27 and the vision to be 'internationally recognised for transforming lives through healthcare innovation, new knowledge and next-generation technologies.'


The GCHKP Office administers precinct governance and advocates on behalf of partners to support precinct development. The Office also manages strategic growth projects and community building, while assisting to drive the commercialisation of key GCHKP technologies with transformative impact.

Businesses interested in locating into the GCHKP's Lumina commercial cluster, or collaborating with Precinct partners

on research, clinical innovation and commercialisation, can contact the GCHKP Office for advice and potential introductions. Investment incentives may be available for eligible businesses locating into the GCHKP.

Products and services

- Business introductions.
- New Development opportunities.
- Business occupancy attraction.
- Startup company support.
- Research partnership opportunities.
- Talent opportunities.
- Investment incentives (for eligible businesses).



Lumina Gold Coast

Lumina is the 9.5-hectare premium commercial cluster, based within the 200-hectare Gold Coast Health and Knowledge Precinct and is the Gold Coast's only commercial location solely dedicated to the health and technology sectors.

Lumina is the Precinct's final development stage and only opportunity to secure premium development-ready commercial land or lease space at the heart of this thriving innovation-based community. A range of premium development-ready sites from 1,000m² to two hectares are available, offering freehold title.

Whether you're a solo operator or start-up requiring shared desk or lab space, a growing or established business seeking multiple floors, or a building of your own, Lumina has a solution to suit you.

Economic Development Queensland (EDQ) is responsible for the development of Lumina over the next 10 to 15 years. EDQ, as part of the Department of State Development, Infrastructure, Local Government and Planning, combines property development with specialist planning functions to create places and investment opportunities for Queenslanders to prosper.

Products and services

- 300 days of sunshine to enjoy the coastal lifestyle.
- Close to three Universities, including Griffith University in the.
- Co-located with Gold Coast University Hospital, Gold Coast Private Hospital and Griffith University.
- Adjacent to residential and retail community,

Smith Collective.

- Benefits from more than \$5 billion of Precinct health, education and transport infrastructure and investment.
- 8 minutes to/from Southport CBD on the G:link light rail.
- 50 minutes' drive from Brisbane and only 12 minutes' drive to great beaches.
- Driving access from two domestic and international airports, with public transport links available.

Accreditations and awards

- RCP Award for Government Leadership, Property Council Australia National Innovation and Excellence Awards 2021.



Contact

P 1300 511 878
E lumina@dcdilgp.qld.gov.au
luminagoldcoast.com.au



My Medical Department

My Medical Department (MMD) is a global medical consultancy, dedicated to delivering pharmaceutical medical expertise to the pharmaceutical industry.

Established under the leadership of Dr. Catherine Ludwig in 2014 in, MMD has since expanded its global presence, maintaining registered offices in both Australia and the UK.

MMD actively supports numerous pharmaceutical companies, delivering medical solutions across Australia and the Asia-Pacific region, Europe and the United States.

As a physician-led team, MMD is committed to upholding patient safety and promoting the quality use of medicines. This commitment enacted through a strong focus on the quality of our work and integrity of our decision-making. We pride ourselves on the quality of our scientific and clinical support, bringing excellence to the development and use of your products throughout their lifecycle.

Their pursuit of excellence ensures that your pharmaceutical endeavours benefit from the highest standards of expertise and professionalism.

Products and services

- Clinical Development and Clinical Operations.
- Medical Writing.
- Medical Affairs.
- Medical Communications and Code Compliance Medical Sign-Off.
- Medical Information.
- Pharmacovigilance.
- Quality and Compliance.
- Strategic Consulting.

Tampe Consulting

Tampe Consulting provides services to companies, tertiary education entities, research institutes, government, and non-for profit and philanthropic organisations.

Services span education and training in IP and commercialisation, advice on IP assessment and protection, technology and research commercialisation, non-dilutive funding ("grants"), business cases, business development, deal structuring and negotiation, and socio-economic impact creation.

Tampe Consulting is led by Dr Jens Tampe, a pro-active executive with deep knowledge and experience in leading engagement between industry and their partners in tertiary academic institutions, government, and philanthropy. Jens has more than 25 years of track record in industry, tertiary academic institutions, and publicly funded research institutions in Australia, Germany, and the USA.

Jens is a proficient translator of innovations, from engagement to closing the deal, to ensure that products and services enter the market and create substantial socio-economic benefits.

Besides his deep knowledge and experience in health, biotechnology, medical devices, ICT, and micro and nano-technology, Jens is experienced in commercialising research outcomes from environmental and social sciences.

Products and services

- Education and training in IP and commercialisation.
- Advice on IP assessment and protection.
- Technology and research commercialisation.
- Support with non-dilutive funding ("grants").
- Business cases.
- Business development.
- Deal structuring and negotiation.
- Socio-economic impact creation.

Contact P +61 433278105
E enquiries@mymedicaldepartment.com
mymedicaldepartment.com

MyMedical
DEPARTMENT
Pharmaceutical Medical Expertise: Anytime, Anywhere.

Contact P +61 468 581 858
E jens@tampeconsulting.com.au
tampeconsulting.godaddysites.com

 **TAMPE CONSULTING**
YOUR PARTNER IN BUSINESS DEVELOPMENT AND ACCELERATION

The Gild Group

The Gild Group is one of Australia's fastest growing fully integrated multidisciplinary professional services firms with a comprehensive suite of best-in-class services across wealth, accounting, finance, legal, insurance, venture capital, incentives and grants and marketing.

Having a great idea is the first step but researching and developing those ideas takes time – and most importantly, money and risk mitigation.

They help make the whole process of identifying and accessing R&D Tax Incentives and Australian Government funding easier. You have their expert team by your side every step of the way, helping you with everything from assessing eligibility, preparing documents, reporting, applications and audit support.

Gild R&D Incentives and Grants, headed up by Renee Levings, has a dedicated and experienced team that can help you navigate the research and development funding landscape to support your innovation and commercialisation strategies.

Products and services

- Multi-disciplinary Professional Services.
- R&D Incentives and Grants.
- Eligibility reviews and compliance services.
- Governance health checks and support.
- Regulator review and audit support.
- Government grant funding support.
- Strategic R&D advisory services.
- Advance and overseas findings support.



AUSTRALIA'S GOLDCOAST.™

Delivered by:



rdagoldcoast.org.au



statedevelopment.qld.gov.au

CITY OF
GOLDCOAST.™

cityofgoldcoast.com.au

HEALTH AND KNOWLEDGE PRECINCT
GOLDCOAST.™

gchkp.com.au

Contact P 1300 843 453
E hello@thegildgroup.com
thegildgroup.com/rdincentivesgrants

 **Innovation
Funding
Managed.**

AUSTRALIA'S
GOLDCOAST.TM